Dynamics of inflammatory markers over six months in patients with asthma who underwent COVID‑19
Abstract
Background. Asthma is a chronic progressive heterogeneous respiratory disease accompanied by the development of a systemic inflammatory response. Due to the widespread prevalence of the novel coronavirus infection, there is concern about the impact of COVID-19 on patients with asthma. Current evidence suggests that SARS-CoV-2 activates the inflammasome response, triggering a hyperinflammatory reaction in patients with asthma, but the long-term consequences are still insufficiently studied.
Purpose. To study the features of the systemic inflammatory process over six months after SARS-COV-2 infection in individuals with asthma.
Materials and methods. In patients with mild, partially controlled asthma after mild COVID-19 infection (n = 52) and individuals with asthma (n = 34) who did not contract COVID-19, an assessment of inflammatory markers in peripheral blood was performed. Patients were examined immediately after recovery and confirmation of a negative SARS-COV-2 test result; one month, three months, and six months after the infection. The control group included conditionally healthy volunteers (n=15) who did not contract COVID-19. The cellular composition of peripheral blood, ESR, CRP, D-dimer levels were determined by classical methods; interleukin concentrations: (IL)-1β, IL-6, IL-18, NOD-like receptor protein 3 (NLRP3) inflammasome, gasdermin D (GSDMD) were measured by ELISA methods.
Results. It was revealed that for all studied parameters, there is a slow decrease in the level of indicators by six months. The levels of GSDMD, platelets, IL-1β, D-dimer, ESR, IL-6, NLRP3 after six months do not reach the values of the control group, which indicates a persistent hyperinflammatory response of the immune system.
Conclusion. Activation of NLRP3 and gasdermin D by the SARS-CoV-2 virus directly or indirectly can lead to dysregulation of inflammasome-mediated mechanisms, triggering and maintaining a hyperinflammatory reaction for six months, prolonging the recovery process in patients with asthma. The study of these processes will expand the understanding of the pathological mechanism. This will allow the development of new therapeutic strategies for asthma patients who have suffered from the novel coronavirus infection.
EDN: USPALS
Downloads
References
Виткина, Т. И., & Лобова, Т. Г. (2022). Динамика параметров периферической крови у здоровых добровольцев, перенёсших COVID 19. В: Актуальные проблемы патофизиологии: Сборник научных статей Международной научно практической конференции (Чита, 11 ноября 2022 года) / Под общей редакцией Н. В. Ларёвой (сс. 39–41). Чита: Читинская государственная медицинская академия. EDN: https://elibrary.ru/ZKDYMV
Vitkina, T. I., Lobova, T. G., Bogomaz, T. T., & Korableva, E. V. (2024). Inflammasome mediated mechanisms of systemic inflammation in COVID 19 and asthma. Russian Open Medical Journal, 13, e0201. https://doi.org/10.15275/rusomj.2024.0201. EDN: https://elibrary.ru/TFBJHT
Глазова, Т. Г., и др. (2011). Изменения свойств тромбоцитов и параметров гемостаза при персистирующем течении бронхиальной астмы у детей. Казанский медицинский журнал, 92(4), 566–568. EDN: https://elibrary.ru/NXZSCX
Коржева, И. Ю., и др. (2012). Нарушение микрогемоциркуляции у больных с бронхолёгочными заболеваниями и методы его изучения. Терапевтический архив, 84(6), 65–67. EDN: https://elibrary.ru/QZLMZP
Щелканов, М. Ю., & Колобухина, Л. В. (2020). COVID 19: этиология, клиническая картина, лечение. Российский журнал инфекций и иммунитета, 10(3), 421–445. https://doi.org/10.15789/2220-7619-CEC-1473. EDN: https://elibrary.ru/IMAADB
A global strategy for the treatment and prevention of bronchial asthma (Rev. 2011). Ed. Belyaevsky, A. S. Moscow: Russian Respiratory Society, 108 p.
Dounce Cuevas, C. A., Flores Flores, A., Bazán, M. S., et al. (2023). Asthma and COVID 19: a controversial relationship. Virology Journal, 20, 207. https://doi.org/10.1186/s12985-023-02174-0. EDN: https://elibrary.ru/ALKJMV
Ge, Q., Chen, X., Zhao, Y., Mu, H., & Zhang, J. (2021). Modulatory mechanisms of NLRP3: potential roles in inflammasome activation. Life Sciences, 267, 118918. https://doi.org/10.1016/j.lfs.2020.118918. EDN: https://elibrary.ru/LZWFMY
Global Initiative for Asthma. (2022). Global strategy for asthma management and prevention [Updated 2022]. https://ginasthma.org/wp-content/uploads/2022/07/GINAMain-Report-2022-FINAL-22-07-WMS.pdf (дата обращения: 24.04.2023)
Lombardi, C., Gani, F., Berti, A., et al. (2021). Asthma and COVID 19: a dangerous liaison? Asthma Research and Practice, 7, 9. https://doi.org/10.1186/s40733-021-00075-z. EDN: https://elibrary.ru/MAXJNU
Paul, O., Tao, J. Q., West, E., et al. (2022). Pulmonary vascular inflammation with fatal coronavirus disease 2019 (COVID 19): possible role for the NLRP3 inflammasome. Respiratory Research, 23, 25. https://doi.org/10.1186/s12931-022-01944-8. EDN: https://elibrary.ru/GJCCVF
Satış, H., Özger, H. S., & Aysert Yıldız, P. (2021). Prognostic value of interleukin 18 and its association with other inflammatory markers and disease severity in COVID 19. Cytokine, 137, 155302. Epub 2020 Sep 29. https://doi.org/10.1016/j.cyto.2020.155302. EDN: https://elibrary.ru/LJMZUC
Simpson, J. L., Phipps, S., Baines, K. J., Oreo, K. M., Gunawardhana, L., & Gibson, P. G. (2014). Elevated expression of the NLRP3 inflammasome in neutrophilic asthma. European Respiratory Journal, 43(4), 1067–1076. https://doi.org/10.1183/09031936.00105013
Xiangyong, Q., Sihao, Z., Qibin, S., Huadong, P., & Pingfeng, Z. (2023). Fantastic voyage: The journey of NLRP3 inflammasome activation. Genes & Diseases, 11(2), 819–829. https://doi.org/10.1016/j.gendis.2023.01.009
Lombardi, C., Gani, F., Berti, A., et al. (2021). Asthma and COVID 19: a dangerous liaison? Asthma Research and Practice, 7, 9. https://doi.org/10.1186/s40733-021-00075-z. EDN: https://elibrary.ru/MAXJNU
Paul, O., Tao, J. Q., West, E., et al. (2022). Pulmonary vascular inflammation with fatal coronavirus disease 2019 (COVID 19): possible role for the NLRP3 inflammasome. Respiratory Research, 23, 25. https://doi.org/10.1186/s12931-022-01944-8. EDN: https://elibrary.ru/GJCCVF
Satış, H., Özger, H. S., & Aysert Yıldız, P. (2021). Prognostic value of interleukin 18 and its association with other inflammatory markers and disease severity in COVID 19. Cytokine, 137, 155302. https://doi.org/10.1016/j.cyto.2020.155302. EDN: https://elibrary.ru/LJMZUC
Simpson, J. L., Phipps, S., Baines, K. J., Oreo, K. M., Gunawardhana, L., & Gibson, P. G. (2014). Elevated expression of the NLRP3 inflammasome in neutrophilic asthma. European Respiratory Journal, 43(4), 1067–1076. https://doi.org/10.1183/09031936.00105013
Weng, J., Li, Y., Li, J., et al. (2021). Gastrointestinal sequelae 90 days after discharge for COVID 19. The Lancet Gastroenterology & Hepatology, 6(5), 344–346. https://doi.org/10.1016/S2468-1253(21)00076-5. EDN: https://elibrary.ru/WZQTZJ
References
Vitkina, T. I., & Lobova, T. G. (2022). Dynamics of peripheral blood parameters in healthy volunteers after COVID 19. In Actual problems of pathophysiology: Collection of scientific articles of the International Scientific and Practical Conference (Chita, November 11, 2022) (pp. 39–41). Chita: Chita State Medical Academy. EDN: https://elibrary.ru/ZKDYMV
Vitkina, T. I., Lobova, T. G., Bogomaz, T. T., & Korableva, E. V. (2024). Inflammasome mediated mechanisms of systemic inflammation in COVID 19 and asthma. Russian Open Medical Journal, 13, e0201. https://doi.org/10.15275/rusomj.2024.0201. EDN: https://elibrary.ru/TFBJHT
Glazova, T. G., et al. (2011). Changes in platelet properties and haemostasis parameters in children with persistent bronchial asthma. Kazan Medical Journal, 92(4), 566–568. EDN: https://elibrary.ru/NXZSCX
Korzheva, I. Yu., et al. (2012). Microcirculation disorders in patients with bronchopulmonary diseases and methods for their study. Therapeutic Archive, 84(6), 65–67. EDN: https://elibrary.ru/QZLMZP
Shchelkanov, M. Yu., & Kolobukhina, L. V. (2020). COVID 19: etiology, clinical presentation, treatment. Russian Journal of Infection and Immunity, 10(3), 421–445. https://doi.org/10.15789/2220-7619-CEC-1473. EDN: https://elibrary.ru/IMAADB
A global strategy for the treatment and prevention of bronchial asthma (Rev. 2011). Ed. Belyaevsky, A. S. Moscow: Russian Respiratory Society, 108 p.
Dounce Cuevas, C. A., Flores Flores, A., Bazán, M. S., et al. (2023). Asthma and COVID 19: a controversial relationship. Virology Journal, 20, 207. https://doi.org/10.1186/s12985-023-02174-0. EDN: https://elibrary.ru/ALKJMV
Ge, Q., Chen, X., Zhao, Y., Mu, H., & Zhang, J. (2021). Modulatory mechanisms of NLRP3: potential roles in inflammasome activation. Life Sciences, 267, 118918. https://doi.org/10.1016/j.lfs.2020.118918. EDN: https://elibrary.ru/LZWFMY
Global Initiative for Asthma. (2022). Global strategy for asthma management and prevention [Updated 2022]. https://ginasthma.org/wp-content/uploads/2022/07/GINAMain-Report-2022-FINAL-22-07-WMS.pdf (дата обращения: 24.04.2023)
Lombardi, C., Gani, F., Berti, A., et al. (2021). Asthma and COVID 19: a dangerous liaison? Asthma Research and Practice, 7, 9. https://doi.org/10.1186/s40733-021-00075-z. EDN: https://elibrary.ru/MAXJNU
Paul, O., Tao, J. Q., West, E., et al. (2022). Pulmonary vascular inflammation with fatal coronavirus disease 2019 (COVID 19): possible role for the NLRP3 inflammasome. Respiratory Research, 23, 25. https://doi.org/10.1186/s12931-022-01944-8. EDN: https://elibrary.ru/GJCCVF
Satış, H., Özger, H. S., & Aysert Yıldız, P. (2021). Prognostic value of interleukin 18 and its association with other inflammatory markers and disease severity in COVID 19. Cytokine, 137, 155302. Epub 2020 Sep 29. https://doi.org/10.1016/j.cyto.2020.155302. EDN: https://elibrary.ru/LJMZUC
Simpson, J. L., Phipps, S., Baines, K. J., Oreo, K. M., Gunawardhana, L., & Gibson, P. G. (2014). Elevated expression of the NLRP3 inflammasome in neutrophilic asthma. European Respiratory Journal, 43(4), 1067–1076. https://doi.org/10.1183/09031936.00105013
Xiangyong, Q., Sihao, Z., Qibin, S., Huadong, P., & Pingfeng, Z. (2023). Fantastic voyage: The journey of NLRP3 inflammasome activation. Genes & Diseases, 11(2), 819–829. https://doi.org/10.1016/j.gendis.2023.01.009
Lombardi, C., Gani, F., Berti, A., et al. (2021). Asthma and COVID 19: a dangerous liaison? Asthma Research and Practice, 7, 9. https://doi.org/10.1186/s40733-021-00075-z. EDN: https://elibrary.ru/MAXJNU
Paul, O., Tao, J. Q., West, E., et al. (2022). Pulmonary vascular inflammation with fatal coronavirus disease 2019 (COVID 19): possible role for the NLRP3 inflammasome. Respiratory Research, 23, 25. https://doi.org/10.1186/s12931-022-01944-8. EDN: https://elibrary.ru/GJCCVF
Satış, H., Özger, H. S., & Aysert Yıldız, P. (2021). Prognostic value of interleukin 18 and its association with other inflammatory markers and disease severity in COVID 19. Cytokine, 137, 155302. https://doi.org/10.1016/j.cyto.2020.155302. EDN: https://elibrary.ru/LJMZUC
Simpson, J. L., Phipps, S., Baines, K. J., Oreo, K. M., Gunawardhana, L., & Gibson, P. G. (2014). Elevated expression of the NLRP3 inflammasome in neutrophilic asthma. European Respiratory Journal, 43(4), 1067–1076. https://doi.org/10.1183/09031936.00105013
Weng, J., Li, Y., Li, J., et al. (2021). Gastrointestinal sequelae 90 days after discharge for COVID 19. The Lancet Gastroenterology & Hepatology, 6(5), 344–346. https://doi.org/10.1016/S2468-1253(21)00076-5. EDN: https://elibrary.ru/WZQTZJ
Copyright (c) 2025 Tatyana G. Lobova, Tatyana I. Vitkina
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
